title: Autologous hematopoietic cell transplantation in multiple sclerosis.
abstract: Autologous haematopoietic cell transplantation (AHCT) is an evolving treatment avenue in multiple sclerosis (MS), which may be highly effective in controlling disease activity and improving disability. However, AHCT is associated with intrinsic toxicities and risks compared with conventional therapies. With growing experience in patient selection and treatment delivery, AHCT is increasingly considered an option in patients with aggressive disease that's responding poorly to disease modifying therapy. Areas covered: This article provides an introduction to AHCT and looks at its development as a treatment for MS over the last 20 years. It also highlights potential mechanisms of action, patient selection, and future trends for this treatment approach. Expert opinion: Currently published data suggest that AHCT's use is associated with significant reduction in MS disease activity and marked improvement in disability when used in patients with highly active relapsing remitting disease. Its long term safety and efficacy have not been fully evaluated but as increasing clinical trial data are published, its use is likely to grow. Further randomised controlled studies are needed to compare AHCT with standard disease modifying therapies and to optimise transplant regimens. Mechanistic studies may provide potential markers for response and a better understanding of disease pathogenesis.
authors.affiliation: a Sheffield Institute of Translational Neuroscience , University of Sheffield , Sheffield , UK.|b Department of Neurology , Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust , Sheffield , UK.
authors.forename: Simon M
authors.initials: SM
authors.lastname: Bell
authors.affiliation: a Sheffield Institute of Translational Neuroscience , University of Sheffield , Sheffield , UK.|b Department of Neurology , Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust , Sheffield , UK.
authors.forename: Basil
authors.initials: B
authors.lastname: Sharrack
authors.affiliation: c Department of Haematology , Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust , Sheffield , UK.|d Department of Oncology and Metabolism , University of Sheffield , UK.
authors.forename: John A
authors.initials: JA
authors.lastname: Snowden
mesh_terms: D000818:Animals; D000068456:Clinical Studies as Topic / Q000379:methods; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000639:trends; D006801:Humans; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D014182:Transplantation, Autologous
keywords: Autologous hematopoietic cell transplantation; EDSS; multiple sclerosis; treatment